<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>beachtrader's Comments</title>
    <description>beachtrader's Comments RSS Syndication from SeekingAlpha.com</description>
    <link>http://seekingalpha.com/user/432136/comments</link>
    <item>
      <title>Will Dendreon Surprise The Street On October 30?</title>
      <link>http://seekingalpha.com/article/938361/comments?source=feed#comment-10882281</link>
      <guid isPermaLink="false">10882281</guid>
      <content>
        <![CDATA[Thanks Ted for clarifying.<br/><br/>This positive news further strengthens the application of Provenge at the onset of the disease. It is terrible that the on-label use (and med insurance restrictions for payments) inhibits to some degree the administration of Provenge at an earlier stages of the disease.<br/><br/>I still believe that doctors employ the easier treatments with poisonous chemo therapy and radiation rather than engage in a cumbersome process...who suffers from this: the patients.<br/><br/>As usual, your article is well written and informative.  Thanks...]]>
      </content>
      <pubDate>Thu, 25 Oct 2012 09:07:22 -0400</pubDate>
      <description>
        <![CDATA[Thanks Ted for clarifying.<br/><br/>This positive news further strengthens the application of Provenge at the onset of the disease. It is terrible that the on-label use (and med insurance restrictions for payments) inhibits to some degree the administration of Provenge at an earlier stages of the disease.<br/><br/>I still believe that doctors employ the easier treatments with poisonous chemo therapy and radiation rather than engage in a cumbersome process...who suffers from this: the patients.<br/><br/>As usual, your article is well written and informative.  Thanks...]]>
      </description>
    </item>
    <item>
      <title>Will Dendreon Surprise The Street On October 30?</title>
      <link>http://seekingalpha.com/article/938361/comments?source=feed#comment-10852821</link>
      <guid isPermaLink="false">10852821</guid>
      <content>
        <![CDATA[Ted...can you explain your comment:<br/><br/>&quot;Patients who received sipuleucel-T (Provenge) developed immune parameters that correlated with improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level and suggesting that these parameters should be the focus of further studies on the treatment.&quot;<br/><br/>Thanks.]]>
      </content>
      <pubDate>Wed, 24 Oct 2012 13:51:55 -0400</pubDate>
      <description>
        <![CDATA[Ted...can you explain your comment:<br/><br/>&quot;Patients who received sipuleucel-T (Provenge) developed immune parameters that correlated with improved overall survival, giving researchers a better understanding of how the immunotherapy works at a cellular level and suggesting that these parameters should be the focus of further studies on the treatment.&quot;<br/><br/>Thanks.]]>
      </description>
    </item>
    <item>
      <title>BP has secured U.S. government permission to ship U.S. crude oil to Canada, and Shell (RDS.A, RDS.B) has applied for a U.S. export license, signs of how the boom in U.S. oil production from shale rock is reshaping its role in the global energy marketplace. Shell declines to say how much oil it planned to export or to which destinations.</title>
      <link>http://seekingalpha.com/currents/post/583321?source=feed#comment-10459971</link>
      <guid isPermaLink="false">10459971</guid>
      <content>
        <![CDATA[I agree ...why are we shipping our subsidized oil to Canada when we import oil here...this is ridiculous.]]>
      </content>
      <pubDate>Fri, 12 Oct 2012 10:03:32 -0400</pubDate>
      <description>
        <![CDATA[I agree ...why are we shipping our subsidized oil to Canada when we import oil here...this is ridiculous.]]>
      </description>
    </item>
    <item>
      <title>Netflix Returns To Predictability</title>
      <link>http://seekingalpha.com/article/906081/comments?source=feed#comment-10281251</link>
      <guid isPermaLink="false">10281251</guid>
      <content>
        <![CDATA[Today (Oct 8, 2012), the hype continues and Whitney Tilson is licking his chops as NFLX continues to advance after Morgan Stanley 's upgrade...does anyone else want to chime in with an upgrade.<br/><br/>The shorts will win on Oct 23...earnings will be impacted by operating losses in Europe, etc.  ]]>
      </content>
      <pubDate>Mon, 08 Oct 2012 09:47:25 -0400</pubDate>
      <description>
        <![CDATA[Today (Oct 8, 2012), the hype continues and Whitney Tilson is licking his chops as NFLX continues to advance after Morgan Stanley 's upgrade...does anyone else want to chime in with an upgrade.<br/><br/>The shorts will win on Oct 23...earnings will be impacted by operating losses in Europe, etc.  ]]>
      </description>
    </item>
    <item>
      <title>Broadcom Should Bounce In Response To Mobile Revenues</title>
      <link>http://seekingalpha.com/article/908381/comments?source=feed#comment-10232791</link>
      <guid isPermaLink="false">10232791</guid>
      <content>
        <![CDATA[BRCM is easily a $40 plus stock but despite all the &quot;Buy&quot; recommendations and positive analysis, BRCM is languishing around $35 (+/-) and not making any real moves.  Why?]]>
      </content>
      <pubDate>Sat, 06 Oct 2012 09:16:03 -0400</pubDate>
      <description>
        <![CDATA[BRCM is easily a $40 plus stock but despite all the &quot;Buy&quot; recommendations and positive analysis, BRCM is languishing around $35 (+/-) and not making any real moves.  Why?]]>
      </description>
    </item>
    <item>
      <title>Netflix Returns To Predictability</title>
      <link>http://seekingalpha.com/article/906081/comments?source=feed#comment-10196601</link>
      <guid isPermaLink="false">10196601</guid>
      <content>
        <![CDATA[You are right about the competition...the ever increasing number of competitors will certainly impact Netflix negatively. Let's see what spin Reed Hastings will present on Oct 23...any streaming increase should be questioned because more people take advantage of the free month and then bail.  Way back when...when streaming became available, he should have charged 1 to 2 dollars extra for those wanting streaming as well. But he wanted to be a pig and greed is blinding.<br/><br/>Whitney Tilson lost millions on his short bet and then reversed his position to long and then lost more millions. So any comments from Tilson should be questioned...he wants out and wants to make money to cover his losses. Why would anyone believe Tilson. And as for Citigroup's biased comments...please...the fundamentals now and going forward do not support a high valuation.<br/><br/>Reed Hastings at the helm of Netflix has proven to be disastrous. ]]>
      </content>
      <pubDate>Fri, 05 Oct 2012 08:45:31 -0400</pubDate>
      <description>
        <![CDATA[You are right about the competition...the ever increasing number of competitors will certainly impact Netflix negatively. Let's see what spin Reed Hastings will present on Oct 23...any streaming increase should be questioned because more people take advantage of the free month and then bail.  Way back when...when streaming became available, he should have charged 1 to 2 dollars extra for those wanting streaming as well. But he wanted to be a pig and greed is blinding.<br/><br/>Whitney Tilson lost millions on his short bet and then reversed his position to long and then lost more millions. So any comments from Tilson should be questioned...he wants out and wants to make money to cover his losses. Why would anyone believe Tilson. And as for Citigroup's biased comments...please...the fundamentals now and going forward do not support a high valuation.<br/><br/>Reed Hastings at the helm of Netflix has proven to be disastrous. ]]>
      </description>
    </item>
    <item>
      <title>Google: Innovating Beyond Advertising And Search</title>
      <link>http://seekingalpha.com/article/830961/comments?source=feed#comment-8854281</link>
      <guid isPermaLink="false">8854281</guid>
      <content>
        <![CDATA[With Google now in a bad position, and with Samsung now shackled with an enormous financial debt and future profits in question if unable to come to terms with Apple going forward, NOKIA may just have a chance to shine again. ]]>
      </content>
      <pubDate>Tue, 28 Aug 2012 11:17:34 -0400</pubDate>
      <description>
        <![CDATA[With Google now in a bad position, and with Samsung now shackled with an enormous financial debt and future profits in question if unable to come to terms with Apple going forward, NOKIA may just have a chance to shine again. ]]>
      </description>
    </item>
    <item>
      <title>Dendreon's Provenge: Early Stage Use</title>
      <link>http://seekingalpha.com/article/817151/comments?source=feed#comment-8587421</link>
      <guid isPermaLink="false">8587421</guid>
      <content>
        <![CDATA[Thanks Ted.   Again this is a no brainer conclusion for effective treatment - i.e., that Provenge be given earlier in treatment rather than after the cancer had metastasized and the immune system compromised and weakened. <br/><br/>Great article...JB]]>
      </content>
      <pubDate>Mon, 20 Aug 2012 15:12:07 -0400</pubDate>
      <description>
        <![CDATA[Thanks Ted.   Again this is a no brainer conclusion for effective treatment - i.e., that Provenge be given earlier in treatment rather than after the cancer had metastasized and the immune system compromised and weakened. <br/><br/>Great article...JB]]>
      </description>
    </item>
    <item>
      <title>Netflix (NFLX) plans to launch its streaming service in Denmark, Sweden, Norway and Finland by the end of the year. The reach into the Scandinavian countries by the company adds to its current non-U.S. base of Canada, Ireland, the U.K., and countries in Latin America.</title>
      <link>http://seekingalpha.com/currents/post/488131?source=feed#comment-8451641</link>
      <guid isPermaLink="false">8451641</guid>
      <content>
        <![CDATA[Andrew...are you surmising that BofA had inside info?  It sure looks like BofA had the inside scoop.]]>
      </content>
      <pubDate>Thu, 16 Aug 2012 05:04:04 -0400</pubDate>
      <description>
        <![CDATA[Andrew...are you surmising that BofA had inside info?  It sure looks like BofA had the inside scoop.]]>
      </description>
    </item>
    <item>
      <title>Dendreon's Provenge Needs To Pull Itself Together Soon</title>
      <link>http://seekingalpha.com/article/748311/comments?source=feed#comment-8220881</link>
      <guid isPermaLink="false">8220881</guid>
      <content>
        <![CDATA[The following was reported in the NY Post - August 7, 2012: <br/>&quot;Chemo May Feed Cancer&quot;<br/>Cancer-fighting chemotherapy can cause damage to healthy cells, triggering them to secrete a protein that sustains tumor growth and resistance to further treatment, a new study in Nature Medicine says. Researchers at the Fred Hutchinson Cancer Research Center in Seattle made the “completely unexpected” finding while seeking to explain why cancer cells are so resilient inside the human body while easy to kill in the lab. (<a rel='nofollow' target='_blank' href='http://nyp.st/MuLc38'>http://nyp.st/MuLc38</a>)<br/><br/>As a former immunologist, I concur with these findings and believe these findings only strengthen the application of Provenge. It is my opinion that doctors prefer an easy pill pushing therapy rather than an intensive therapy. Regrettably, patients are denied a therapy program that produces results and, if applied during the early stages, we would see survival rates beyond current expectations.<br/><br/>A friend of mine is now suffering from the effects of chemo and radiation with liver, stomach and colon damage and, after surgery to correct some damage, he still suffers digestive disorders and his quality of life greatly reduced.  A large portion of his liver is irreparably damaged.<br/><br/>On the QT, studies are now being conducted to determine the effects of radiation and chemo on patients who are now succumbing to the effects of such treatments. <br/><br/>Sadly, Prostate cancer patients treated with chemo and radiation succumb to the effects of chemo and radiation without knowing that these treatments brought about collateral effects resulting in untimely death.<br/><br/>I still believe that Provenge provides the safest and effective treatment for long term survival...]]>
      </content>
      <pubDate>Wed, 08 Aug 2012 16:23:12 -0400</pubDate>
      <description>
        <![CDATA[The following was reported in the NY Post - August 7, 2012: <br/>&quot;Chemo May Feed Cancer&quot;<br/>Cancer-fighting chemotherapy can cause damage to healthy cells, triggering them to secrete a protein that sustains tumor growth and resistance to further treatment, a new study in Nature Medicine says. Researchers at the Fred Hutchinson Cancer Research Center in Seattle made the “completely unexpected” finding while seeking to explain why cancer cells are so resilient inside the human body while easy to kill in the lab. (<a rel='nofollow' target='_blank' href='http://nyp.st/MuLc38'>http://nyp.st/MuLc38</a>)<br/><br/>As a former immunologist, I concur with these findings and believe these findings only strengthen the application of Provenge. It is my opinion that doctors prefer an easy pill pushing therapy rather than an intensive therapy. Regrettably, patients are denied a therapy program that produces results and, if applied during the early stages, we would see survival rates beyond current expectations.<br/><br/>A friend of mine is now suffering from the effects of chemo and radiation with liver, stomach and colon damage and, after surgery to correct some damage, he still suffers digestive disorders and his quality of life greatly reduced.  A large portion of his liver is irreparably damaged.<br/><br/>On the QT, studies are now being conducted to determine the effects of radiation and chemo on patients who are now succumbing to the effects of such treatments. <br/><br/>Sadly, Prostate cancer patients treated with chemo and radiation succumb to the effects of chemo and radiation without knowing that these treatments brought about collateral effects resulting in untimely death.<br/><br/>I still believe that Provenge provides the safest and effective treatment for long term survival...]]>
      </description>
    </item>
    <item>
      <title>Dendreon Cuts Jobs As It Battles Weak Sales</title>
      <link>http://seekingalpha.com/article/779091/comments?source=feed#comment-8220621</link>
      <guid isPermaLink="false">8220621</guid>
      <content>
        <![CDATA[Ted…I have been retired from immunological research for the past 20 years having made a career change from science to the financial sector…have yet to decide whether I made the right decision.  In response to your query regarding my thoughts, you can appreciate the difficulties that we encounter whenever we introduce a foreign substance or chemical to target a disease that we have yet to get an understanding due to its organ specific origin and then to its metastatic invasive transformation.  Although I do not have a scientific explanation since I am not familiar with the specific action of the drugs in question, the cancellation effect of these drugs is not surprising given the attack mechanism response of cancerous cells to any perceived structural similarities and I can readily appreciate the negative impact of such potent drugs [abiraterone (Zytiga) and docetaxel (Taxotere)] used in conjunction or applied following the other.  These drugs do affect other cellular organs in the body as well…especially filtering organs.  And then there is the aspect that not every human is similar…not everyone reacts to drug treatment in a similar fashion…hence, different survival horizons.  My comments are based purely on an educational basis.  <br/><br/>My goodness, I listen to pharmacological drug commercials on TV and ask myself who would want to take these drugs…the side effects are worse than the illness…some side effects can even cause death.  But it is noted that not everyone will experience the same side effects…that such side effects are being reported by different users with different genetic characteristics.  What is the FDA thinking when the FDA approves these medications with death being a potential side effect?  <br/><br/>With regard to Provenge, similar to a vaccine in nature with its antibody production effect, many efficacious vaccines are based on the isolation of a specific bacterial/cellular antigens and the introduction of these antigens to the human body for the production of antibodies.  Provenge should be applied earlier with the onset of diagnosis while the immune system is viable and not compromised.  Sadly, the years necessary to conduct trials and the financial costs pose restrictive time constraints when so many are succumbing to Prostate Cancer.  And any off-label use is not generally covered by medical insurance. ]]>
      </content>
      <pubDate>Wed, 08 Aug 2012 16:16:31 -0400</pubDate>
      <description>
        <![CDATA[Ted…I have been retired from immunological research for the past 20 years having made a career change from science to the financial sector…have yet to decide whether I made the right decision.  In response to your query regarding my thoughts, you can appreciate the difficulties that we encounter whenever we introduce a foreign substance or chemical to target a disease that we have yet to get an understanding due to its organ specific origin and then to its metastatic invasive transformation.  Although I do not have a scientific explanation since I am not familiar with the specific action of the drugs in question, the cancellation effect of these drugs is not surprising given the attack mechanism response of cancerous cells to any perceived structural similarities and I can readily appreciate the negative impact of such potent drugs [abiraterone (Zytiga) and docetaxel (Taxotere)] used in conjunction or applied following the other.  These drugs do affect other cellular organs in the body as well…especially filtering organs.  And then there is the aspect that not every human is similar…not everyone reacts to drug treatment in a similar fashion…hence, different survival horizons.  My comments are based purely on an educational basis.  <br/><br/>My goodness, I listen to pharmacological drug commercials on TV and ask myself who would want to take these drugs…the side effects are worse than the illness…some side effects can even cause death.  But it is noted that not everyone will experience the same side effects…that such side effects are being reported by different users with different genetic characteristics.  What is the FDA thinking when the FDA approves these medications with death being a potential side effect?  <br/><br/>With regard to Provenge, similar to a vaccine in nature with its antibody production effect, many efficacious vaccines are based on the isolation of a specific bacterial/cellular antigens and the introduction of these antigens to the human body for the production of antibodies.  Provenge should be applied earlier with the onset of diagnosis while the immune system is viable and not compromised.  Sadly, the years necessary to conduct trials and the financial costs pose restrictive time constraints when so many are succumbing to Prostate Cancer.  And any off-label use is not generally covered by medical insurance. ]]>
      </description>
    </item>
    <item>
      <title>Dendreon Cuts Jobs As It Battles Weak Sales</title>
      <link>http://seekingalpha.com/article/779091/comments?source=feed#comment-8203521</link>
      <guid isPermaLink="false">8203521</guid>
      <content>
        <![CDATA[<br/>The following was reported in the NY Post - August 7, 2012: <br/>&quot;Chemo May Feed Cancer&quot;<br/>Cancer-fighting chemotherapy can cause damage to healthy cells, triggering them to secrete a protein that sustains tumor growth and resistance to further treatment, a new study in Nature Medicine says. Researchers at the Fred Hutchinson Cancer Research Center in Seattle made the “completely unexpected” finding while seeking to explain why cancer cells are so resilient inside the human body while easy to kill in the lab. (<a rel='nofollow' target='_blank' href='http://nyp.st/MuLc38'>http://nyp.st/MuLc38</a>)<br/><br/>As a former immunologist, I concur with these findings and believe these findings only strengthen the application of Provenge. It is my opinion that doctors prefer an easy pill pushing therapy rather than an intensive therapy. Regrettably, patients are denied a therapy program that produces results and, if applied during the early stages, we would see survival rates beyond current expectations.<br/><br/>A friend of mine is now suffering from the effects of chemo and radiation with liver, stomach and colon damage and, after surgery to correct some damage, he still suffers digestive disorders and his quality of life greatly reduced.<br/><br/>On the QT, studies are now being conducted to determine the effects of radiation and chemo on patients who are now succumbing to the effects of such treatments. <br/> <br/>Sadly, Prostate cancer patients treated with chemo and radiation succumb to the effects of chemo and radiation without knowing that these treatments brought about collateral effects resulting in untimely death.<br/> <br/>I still believe that Provenge provides the safest and effective treatment for long term survival...<br/> ]]>
      </content>
      <pubDate>Wed, 08 Aug 2012 09:50:28 -0400</pubDate>
      <description>
        <![CDATA[<br/>The following was reported in the NY Post - August 7, 2012: <br/>&quot;Chemo May Feed Cancer&quot;<br/>Cancer-fighting chemotherapy can cause damage to healthy cells, triggering them to secrete a protein that sustains tumor growth and resistance to further treatment, a new study in Nature Medicine says. Researchers at the Fred Hutchinson Cancer Research Center in Seattle made the “completely unexpected” finding while seeking to explain why cancer cells are so resilient inside the human body while easy to kill in the lab. (<a rel='nofollow' target='_blank' href='http://nyp.st/MuLc38'>http://nyp.st/MuLc38</a>)<br/><br/>As a former immunologist, I concur with these findings and believe these findings only strengthen the application of Provenge. It is my opinion that doctors prefer an easy pill pushing therapy rather than an intensive therapy. Regrettably, patients are denied a therapy program that produces results and, if applied during the early stages, we would see survival rates beyond current expectations.<br/><br/>A friend of mine is now suffering from the effects of chemo and radiation with liver, stomach and colon damage and, after surgery to correct some damage, he still suffers digestive disorders and his quality of life greatly reduced.<br/><br/>On the QT, studies are now being conducted to determine the effects of radiation and chemo on patients who are now succumbing to the effects of such treatments. <br/> <br/>Sadly, Prostate cancer patients treated with chemo and radiation succumb to the effects of chemo and radiation without knowing that these treatments brought about collateral effects resulting in untimely death.<br/> <br/>I still believe that Provenge provides the safest and effective treatment for long term survival...<br/> ]]>
      </description>
    </item>
    <item>
      <title>What's Up With Dendreon And Medivation Today?</title>
      <link>http://seekingalpha.com/article/669651/comments?source=feed#comment-6837421</link>
      <guid isPermaLink="false">6837421</guid>
      <content>
        <![CDATA[Thank you Ted for clarifying any misinformation. As an DNDN investor, I am disheartened by any misleading statements presented by analysts who fail to note critical factors in the development of Provenge and the costs associated with its manufacture. I will always remember the analyst who appeared on TV prior to Provenge FDA approval and said that DNDN would skyrocket to $60 on the approval...the analyst failed to inform the audience that there were reimbursement and insurance issues as well as manufacturing expenditures that have yet to be resolved at that time...then when these issues came to the forefront and ultimately resolved, many investors got burnt. <br/><br/>The tragedy is that Provenge treatment, especially if given during the early stages of prostate cancer detection, is the safest and best treatment possible. But doctors want a quick and easy medical application and will sacrifice the patient's well being for a quick remedy that has yet been tested in the long term.<br/><br/>The effects of radiation and chemo are highly toxic and detrimental to the human body....]]>
      </content>
      <pubDate>Wed, 27 Jun 2012 08:22:09 -0400</pubDate>
      <description>
        <![CDATA[Thank you Ted for clarifying any misinformation. As an DNDN investor, I am disheartened by any misleading statements presented by analysts who fail to note critical factors in the development of Provenge and the costs associated with its manufacture. I will always remember the analyst who appeared on TV prior to Provenge FDA approval and said that DNDN would skyrocket to $60 on the approval...the analyst failed to inform the audience that there were reimbursement and insurance issues as well as manufacturing expenditures that have yet to be resolved at that time...then when these issues came to the forefront and ultimately resolved, many investors got burnt. <br/><br/>The tragedy is that Provenge treatment, especially if given during the early stages of prostate cancer detection, is the safest and best treatment possible. But doctors want a quick and easy medical application and will sacrifice the patient's well being for a quick remedy that has yet been tested in the long term.<br/><br/>The effects of radiation and chemo are highly toxic and detrimental to the human body....]]>
      </description>
    </item>
    <item>
      <title> Morgan Stanley (MS -2.6%) has offered a price adjustment to Facebook (FB +2.5%) investors in the event they overpaid due to order execution problems, Dow Jones reports. The news comes as lawsuits fly, politicians huff and puff, and sources tell the WSJ MS and other underwriters have made a $100M profit through &quot;greenshoe&quot; short positions on Facebook shares (Felix Salmon recently explained the arrangement in detail). </title>
      <link>http://seekingalpha.com/currents/post/332971?source=feed#comment-5787351</link>
      <guid isPermaLink="false">5787351</guid>
      <content>
        <![CDATA[Who (MS?) is managing to maintain FB above $30? Even at $30, the FB stock is not worth the paper it is printed on. Bragging rights of ownership is not worth the cost of admission.]]>
      </content>
      <pubDate>Thu, 24 May 2012 18:11:00 -0400</pubDate>
      <description>
        <![CDATA[Who (MS?) is managing to maintain FB above $30? Even at $30, the FB stock is not worth the paper it is printed on. Bragging rights of ownership is not worth the cost of admission.]]>
      </description>
    </item>
    <item>
      <title>Morgan Stanley Governance Issue</title>
      <link>http://seekingalpha.com/article/615061/comments?source=feed#comment-5787161</link>
      <guid isPermaLink="false">5787161</guid>
      <content>
        <![CDATA[I agree with you...bank robbers are punished and sent to jail...time to send the inside bank robbers to jail.   ]]>
      </content>
      <pubDate>Thu, 24 May 2012 18:03:22 -0400</pubDate>
      <description>
        <![CDATA[I agree with you...bank robbers are punished and sent to jail...time to send the inside bank robbers to jail.   ]]>
      </description>
    </item>
    <item>
      <title> The $100M trading profit that underwriters are reported to have made by &quot;greenshoe&quot; short positions on Facebook may seem &quot;like a giant conflict of interest,&quot; outside of Wall Street writes Fortune's Stephen Gandel, but no rules were broken and the potential trades were even disclosed in Facebook's prospectus.&quot; </title>
      <link>http://seekingalpha.com/currents/post/334771?source=feed#comment-5786391</link>
      <guid isPermaLink="false">5786391</guid>
      <content>
        <![CDATA[It may not be illegal but try telling that to the investors that MS sold to!]]>
      </content>
      <pubDate>Thu, 24 May 2012 17:44:03 -0400</pubDate>
      <description>
        <![CDATA[It may not be illegal but try telling that to the investors that MS sold to!]]>
      </description>
    </item>
    <item>
      <title>Morgan Stanley Slaughter</title>
      <link>http://seekingalpha.com/article/608331/comments?source=feed#comment-5714611</link>
      <guid isPermaLink="false">5714611</guid>
      <content>
        <![CDATA[Banks are doing everything and anything these days to make a dollar...ethics in banking no longer exists.   ]]>
      </content>
      <pubDate>Tue, 22 May 2012 23:10:27 -0400</pubDate>
      <description>
        <![CDATA[Banks are doing everything and anything these days to make a dollar...ethics in banking no longer exists.   ]]>
      </description>
    </item>
    <item>
      <title>JPMorgan Will Continue To Tumble On $2 Billion Mess</title>
      <link>http://seekingalpha.com/article/608531/comments?source=feed#comment-5709211</link>
      <guid isPermaLink="false">5709211</guid>
      <content>
        <![CDATA[It is rather ironic that the Volker Rule prohibits risky trades with customer funds...thereby pushing the envelope and JPM took riskier trades to make money on investment and derivative trades...the gamble did not roll in JPM's favor. If the gamble paid off, no one would be the wiser and JPM would continue to be Wall Street's darling. ]]>
      </content>
      <pubDate>Tue, 22 May 2012 19:00:00 -0400</pubDate>
      <description>
        <![CDATA[It is rather ironic that the Volker Rule prohibits risky trades with customer funds...thereby pushing the envelope and JPM took riskier trades to make money on investment and derivative trades...the gamble did not roll in JPM's favor. If the gamble paid off, no one would be the wiser and JPM would continue to be Wall Street's darling. ]]>
      </description>
    </item>
    <item>
      <title> Driving home its commitment to financing original programming at the expense of library size, Netflix (NFLX -5.6%) has created a new position of VP of Original Content. Filling the position is content acquisition VP Cindy Holland, whose current job will be assumed by Latin America/Canada content acquisition chief Jason Ropell. The shakeup comes on a day when Netflix made new lows for 2012. </title>
      <link>http://seekingalpha.com/currents/post/331211?source=feed#comment-5707941</link>
      <guid isPermaLink="false">5707941</guid>
      <content>
        <![CDATA[Nothing can stop the blood streaming.]]>
      </content>
      <pubDate>Tue, 22 May 2012 18:30:26 -0400</pubDate>
      <description>
        <![CDATA[Nothing can stop the blood streaming.]]>
      </description>
    </item>
    <item>
      <title> Massachusetts subpoenas Morgan Stanley over the Facebook IPO amid allegations about leaked negative views. MS -1.4% AH. </title>
      <link>http://seekingalpha.com/currents/post/331121?source=feed#comment-5707711</link>
      <guid isPermaLink="false">5707711</guid>
      <content>
        <![CDATA[It is time that the underwriters (MS et al) be heavily fined for insider trading...passing info selectively is a form of insider trading while uninformed invewstors are taken to the cleaners. I hope that investors by-pass IPOs in the future and let the institutional investors hold the hyped securities.]]>
      </content>
      <pubDate>Tue, 22 May 2012 18:25:15 -0400</pubDate>
      <description>
        <![CDATA[It is time that the underwriters (MS et al) be heavily fined for insider trading...passing info selectively is a form of insider trading while uninformed invewstors are taken to the cleaners. I hope that investors by-pass IPOs in the future and let the institutional investors hold the hyped securities.]]>
      </description>
    </item>
    <item>
      <title> Analysts at Facebook's (FB) lead underwriters cut their revenue estimates ahead of the IPO, reports Reuters, passing the information on to a few of their key clients. &quot;My biggest hedge fund client told me they lowered their numbers right around mid-roadshow,&quot; says an IPO researcher. He still bought the issue, he says, but flipped it immediately and went short. Shares -3.8% premarket. </title>
      <link>http://seekingalpha.com/currents/post/329341?source=feed#comment-5703851</link>
      <guid isPermaLink="false">5703851</guid>
      <content>
        <![CDATA[FB is definitely overvalued and overrated ...FB is a social entity and who pays attention to ads when the participants just want to socially connect. FB will find it difficult to monetize and retailers will just bail out. FB is not a GOOGLE...but a GAGGLE.<br/><br/>FB was overhyped from the start...the underwriters were greedy.]]>
      </content>
      <pubDate>Tue, 22 May 2012 16:25:28 -0400</pubDate>
      <description>
        <![CDATA[FB is definitely overvalued and overrated ...FB is a social entity and who pays attention to ads when the participants just want to socially connect. FB will find it difficult to monetize and retailers will just bail out. FB is not a GOOGLE...but a GAGGLE.<br/><br/>FB was overhyped from the start...the underwriters were greedy.]]>
      </description>
    </item>
    <item>
      <title> Just two days after JPMorgan (JPM) announced a massive $2B trading loss, Pimco's Bill Gross comes to its defense, calling it one of the &amp;ldquo;best-run banks in the world.&quot; It&amp;rsquo;s a decently capitalized bank, Gross says, with $120B of Tier-1 capital. &quot;That&amp;rsquo;s 10.5%, which is higher than the 9% U.S. average.&amp;rdquo; And capital quality, according to Pimco, is what you need to trust most in a situation like this. </title>
      <link>http://seekingalpha.com/currents/post/313491?source=feed#comment-5382711</link>
      <guid isPermaLink="false">5382711</guid>
      <content>
        <![CDATA[The government has made it very difficult for banks to make money trading for their own account so JPM took a bigger risk and lost the bet!!!!!]]>
      </content>
      <pubDate>Sat, 12 May 2012 21:39:52 -0400</pubDate>
      <description>
        <![CDATA[The government has made it very difficult for banks to make money trading for their own account so JPM took a bigger risk and lost the bet!!!!!]]>
      </description>
    </item>
    <item>
      <title>What Does Netflix's $14,500,000 Insider Purchase Mean?</title>
      <link>http://seekingalpha.com/article/582691/comments?source=feed#comment-5363671</link>
      <guid isPermaLink="false">5363671</guid>
      <content>
        <![CDATA[Please...this is nothing more than a hype and dump scam.<br/><br/>They want you to believe that there is something in the works to get people interested in buying the stuck and then they will dump.]]>
      </content>
      <pubDate>Fri, 11 May 2012 22:30:20 -0400</pubDate>
      <description>
        <![CDATA[Please...this is nothing more than a hype and dump scam.<br/><br/>They want you to believe that there is something in the works to get people interested in buying the stuck and then they will dump.]]>
      </description>
    </item>
    <item>
      <title>For Dendreon There's A Little Light, But A Lot Of Tunnel</title>
      <link>http://seekingalpha.com/article/570041/comments?source=feed#comment-5325711</link>
      <guid isPermaLink="false">5325711</guid>
      <content>
        <![CDATA[Why is MDVN $75 to $80 when it does not earn any money to speak of and FDA has yet to approve MDVN's drug for prostate cancer?]]>
      </content>
      <pubDate>Thu, 10 May 2012 23:22:55 -0400</pubDate>
      <description>
        <![CDATA[Why is MDVN $75 to $80 when it does not earn any money to speak of and FDA has yet to approve MDVN's drug for prostate cancer?]]>
      </description>
    </item>
    <item>
      <title>Netflix: Limited Downside, Significant Upside</title>
      <link>http://seekingalpha.com/article/577921/comments?source=feed#comment-5324731</link>
      <guid isPermaLink="false">5324731</guid>
      <content>
        <![CDATA[I agree with CONTRARIETY...there is still more downside risk as the competition heats up and as free subscribers stream in and out of Netflix.  Hastings' blunders have soured investor confidence and trust in Hastings capability in managing NETFLIX. Does Whitney Tilson still have long positions?]]>
      </content>
      <pubDate>Thu, 10 May 2012 22:31:05 -0400</pubDate>
      <description>
        <![CDATA[I agree with CONTRARIETY...there is still more downside risk as the competition heats up and as free subscribers stream in and out of Netflix.  Hastings' blunders have soured investor confidence and trust in Hastings capability in managing NETFLIX. Does Whitney Tilson still have long positions?]]>
      </description>
    </item>
    <item>
      <title> Dendreon (DNDN) posted a narrower Q1 loss, but shares -11.9% premarket as sales of its Provenge prostate cancer vaccine rose 6.5% Y/Y, with low single-digit growth predicted for Q2. Analysts are  concerned over the level of sales growth and that profit margins for DNDN&amp;rsquo;s only approved product aren&amp;rsquo;t high enough. A Citi analyst says the &quot;only upside&quot; in the stock comes from potential acquisition. </title>
      <link>http://seekingalpha.com/currents/post/303491?source=feed#comment-5211231</link>
      <guid isPermaLink="false">5211231</guid>
      <content>
        <![CDATA[The cost to manufacture Provenge and to treat patients with Provenge is high; and so too are the benefits: survival and a greater quality of life. I am hoping that doctors will consider the patient's best option and opt for Provenge treatment.<br/><br/>Sadly, all the issues confronting Dendreon (FDA approval, insurance reimbursement, treatment cost, treatment accessibility, acceptance of treatment, etc.) were ignored by the analysts. The analysts predictions drove the stock price...and many investors bought in.   The treatment is excellent...I am long dndn.]]>
      </content>
      <pubDate>Tue, 08 May 2012 09:32:37 -0400</pubDate>
      <description>
        <![CDATA[The cost to manufacture Provenge and to treat patients with Provenge is high; and so too are the benefits: survival and a greater quality of life. I am hoping that doctors will consider the patient's best option and opt for Provenge treatment.<br/><br/>Sadly, all the issues confronting Dendreon (FDA approval, insurance reimbursement, treatment cost, treatment accessibility, acceptance of treatment, etc.) were ignored by the analysts. The analysts predictions drove the stock price...and many investors bought in.   The treatment is excellent...I am long dndn.]]>
      </description>
    </item>
    <item>
      <title>Dendreon's Boring Q1 Results</title>
      <link>http://seekingalpha.com/article/568431/comments?source=feed#comment-5209731</link>
      <guid isPermaLink="false">5209731</guid>
      <content>
        <![CDATA[What is needed is positive feed back from survivors after treatment with Provenge. I strongly believe in the concept and would like to see off-label use during initial phases after diagnosis. I am sure that the pill pushers would object to any treatment that would jeopardize their relationship with the big pharmaceuticals.]]>
      </content>
      <pubDate>Tue, 08 May 2012 09:02:37 -0400</pubDate>
      <description>
        <![CDATA[What is needed is positive feed back from survivors after treatment with Provenge. I strongly believe in the concept and would like to see off-label use during initial phases after diagnosis. I am sure that the pill pushers would object to any treatment that would jeopardize their relationship with the big pharmaceuticals.]]>
      </description>
    </item>
    <item>
      <title>Chesapeake Energy: Investors Fume Over Pattern Of Poor Corporate Governance</title>
      <link>http://seekingalpha.com/article/563691/comments?source=feed#comment-5195031</link>
      <guid isPermaLink="false">5195031</guid>
      <content>
        <![CDATA[Will someone educate me. Is not the role of the hedge fund to bet against either long or short positions? So McClendon was betting against the price of gas going up (contra to the wishes of CHK stock holders)...by overproducing gas, the price of gas goes down.<br/><br/>McClendon should be fired!!!!! And all pensions, etc, forfeited!!!]]>
      </content>
      <pubDate>Mon, 07 May 2012 17:45:05 -0400</pubDate>
      <description>
        <![CDATA[Will someone educate me. Is not the role of the hedge fund to bet against either long or short positions? So McClendon was betting against the price of gas going up (contra to the wishes of CHK stock holders)...by overproducing gas, the price of gas goes down.<br/><br/>McClendon should be fired!!!!! And all pensions, etc, forfeited!!!]]>
      </description>
    </item>
    <item>
      <title> Netflix (NFLX -7.6%) closed at levels last seen in early January after Viacom (VIA, VIAB) stated on its FQ2 earnings call Epix's movies will be available on Netflix &quot;under any circumstance,&quot; but other streaming partners might also be added. Last week, it was reported Apple (AAPL) is talking to Epix, which Viacom co-owns with LGF and MGM, about a streaming deal. Netflix's exclusivity ends in September. </title>
      <link>http://seekingalpha.com/currents/post/295901?source=feed#comment-5082391</link>
      <guid isPermaLink="false">5082391</guid>
      <content>
        <![CDATA[Read Hastings is an arrogant mega maniac who destroyed Whitney Tilson...Whitney would have become a billionaire with his short positions had he not been intimidated by Hastings. Tilson subsequently went long...now losing millions!!!!!!!!!!!!!!!!]]>
      </content>
      <pubDate>Thu, 03 May 2012 21:23:27 -0400</pubDate>
      <description>
        <![CDATA[Read Hastings is an arrogant mega maniac who destroyed Whitney Tilson...Whitney would have become a billionaire with his short positions had he not been intimidated by Hastings. Tilson subsequently went long...now losing millions!!!!!!!!!!!!!!!!]]>
      </description>
    </item>
    <item>
      <title> The Chesapeake (CHK -13%) Q1 call has ended, and aside from McClendon's opening remarks - &quot;a great deal of misinformation&quot; has been published, he's &quot;deeply sorry for all the distractions&quot; - analysts (screened?) focused on CHK's asset monetization and debt reduction plans. CHK continues to emphasize its move from gas to oil, and says it's on track to meet debt  reduction targets. </title>
      <link>http://seekingalpha.com/currents/post/289521?source=feed#comment-5031601</link>
      <guid isPermaLink="false">5031601</guid>
      <content>
        <![CDATA[CHK not worth a cent as long as McClendon is associated with any management role. Where is Carl Icahn?]]>
      </content>
      <pubDate>Wed, 02 May 2012 17:02:12 -0400</pubDate>
      <description>
        <![CDATA[CHK not worth a cent as long as McClendon is associated with any management role. Where is Carl Icahn?]]>
      </description>
    </item>
  </channel>
</rss>
